<DOC>
	<DOCNO>NCT01711736</DOCNO>
	<brief_summary>The purpose study investigate immunogenicity , reactogenicity safety new influenza vaccine GSK2282512A ( FLU-Q-QIV ) compare activity market vaccine Fluarix® ( TIV ) young child 6 35 month age .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Quadrivalent Influenza Vaccine GSK2282512A When Administered Children 6 35 Months Age</brief_title>
	<detailed_description>The subject randomize ( 1:1 ) 2 treatment group explore response vaccination sub-group analysis base age ( 6 17 month , 18 35 month ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject 's parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . A male female , include , 6 35 month age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Subjects stable health determine investigator 's clinical examination assessment subject 's medical history . Subjects eligible regardless history administration influenza vaccine previous season . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Routine register childhood vaccination permit . Child care . Prior receipt seasonal pandemic influenza vaccine within six month precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . History GuillainBarré syndrome within six week receipt prior influenza vaccine . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Acute disease and/or fever time enrolment . Any significant disorder coagulation treatment warfarin derivative heparin . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Children</keyword>
	<keyword>Safety</keyword>
	<keyword>Seasonal influenza</keyword>
	<keyword>Fluarix</keyword>
</DOC>